+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antifungal Drugs Market by Drug Class, Dosage Form, Species, Route of Administration, Therapeutic Area, Distribution Channel, End Use, Patient Age Group - Global Forecast 2026-2032- Product Image
Antifungal Drugs Market by Drug Class, Dosage Form, Species, Route of Administration, Therapeutic Area, Distribution Channel, End Use, Patient Age Group - Global Forecast 2026-2032- Product Image
Sale

Antifungal Drugs Market by Drug Class, Dosage Form, Species, Route of Administration, Therapeutic Area, Distribution Channel, End Use, Patient Age Group - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337228
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antifungal Drugs Market is projected to reach USD 17.81 Billion in 2026. It is expected to continue growing at a CAGR of 6.39%, reaching USD 25.93 Billion by 2032.

The antifungal drugs market is moving from a largely treatment-driven category toward a strategic infectious disease priority shaped by rising immunocompromised populations, hospital-acquired fungal threats, and documented antifungal resistance. Peer-reviewed global health literature has linked fungal diseases to millions of severe infections each year, while the WHO Fungal Priority Pathogens List identifies Candida auris, Aspergillus fumigatus, Cryptococcus neoformans, and Candida albicans among the most consequential pathogens for research and public health planning.

Demand spans systemic antifungals for invasive candidiasis, aspergillosis, cryptococcosis, and mucormycosis, as well as topical and oral therapies for dermatophytosis and mucosal infections. Growth is supported by improved diagnostics, expanding transplant and oncology care, broader ICU utilization, and the need for safer, resistance-aware therapies with fewer drug interactions and more convenient dosing across inpatient and outpatient care pathways.

Transformative Shifts in the Antifungal Landscape

The antifungal drugs landscape is being reshaped by resistance surveillance, novel mechanisms of action, and changing site-of-care economics. Echinocandins, azoles, polyenes, allylamines, and flucytosine remain essential, but clinical limitations such as nephrotoxicity, hepatotoxicity, CYP-mediated interactions, infusion requirements, and emerging non-susceptibility are increasing the value of targeted antifungal innovation.

Recent regulatory activity and late-stage development demonstrate the shift. FDA approval of ibrexafungerp introduced an oral glucan synthase inhibitor option for vulvovaginal candidiasis, while rezafungin added a once-weekly echinocandin for candidemia and invasive candidiasis. Pipeline attention around agents such as olorofim and fosmanogepix reflects demand for differentiated activity against resistant and hard-to-treat fungi, particularly where current antifungal drug classes remain constrained by toxicity, resistance, or limited spectrum.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating antifungal drug discovery by improving compound screening, structure-based design, toxicity prediction, and repurposing analysis. Because fungal cells share many biological similarities with human cells, selectivity has historically constrained antifungal development; AI-enabled modeling can help prioritize candidates with stronger pathogen targeting and lower host toxicity risk before costly experimental validation.

AI also supports clinical decision-making through faster image interpretation, genomic resistance detection, electronic health record-based risk scoring, and predictive identification of high-risk patients in oncology, transplant, HIV, and intensive care settings. Its cumulative value will be highest when paired with validated diagnostics, curated mycology datasets, antimicrobial stewardship programs, pharmacovigilance systems, and prospective clinical evidence that confirms improvements in time-to-treatment, treatment selection, and patient outcomes.

Key Regional Insights for Antifungal Drugs

North America remains a high-priority region for antifungal drugs due to advanced infectious disease diagnostics, broad hospital stewardship programs, and CDC-led attention to Candida auris as an urgent antimicrobial resistance threat. Europe benefits from coordinated surveillance, hospital-based antifungal stewardship, and regional policy alignment on antimicrobial resistance preparedness, while Latin America continues to see demand influenced by HIV care, diabetes prevalence, recurrent superficial mycoses, and persistent access gaps in specialist diagnostics and susceptibility testing.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in tertiary care, oncology, transplant capacity, and laboratory infrastructure, strengthening demand for systemic antifungals and rapid fungal diagnostics. The Middle East, particularly advanced Gulf health systems, is adopting high-acuity infectious disease care supported by modern hospitals and specialist centers, while Africa faces the heaviest access challenge for cryptococcal disease, histoplasmosis, and HIV-associated fungal infections, making affordable diagnostics, essential antifungals, and guideline-based care central to public health impact.

Key Group Insights Across Major Economic Blocs

ASEAN demand is supported by expanding hospital infrastructure, humid climates associated with superficial mycoses, and growing access to specialty care in Singapore, Thailand, Indonesia, Vietnam, Malaysia, and the Philippines. The GCC is characterized by high healthcare spending, medical tourism, advanced private and public hospitals, and demand for systemic antifungals in oncology, transplant, intensive care, and complex surgical settings.

The European Union emphasizes stewardship, pharmacovigilance, infection prevention, and coordinated antimicrobial resistance policy, creating a strong environment for evidence-based antifungal use. BRICS countries combine large patient populations with rising tertiary care utilization, domestic pharmaceutical capacity, and uneven diagnostic access, while the G7 drives premium innovation, regulatory science, reimbursement standards, and clinical guideline adoption. NATO members add defense-health relevance because fungal outbreak readiness, medicine stockpiling, and resilient hospital systems are increasingly viewed as part of broader health security preparedness.

Key Country Insights for Antifungal Drugs

The United States leads in clinical adoption, FDA-regulated innovation, hospital surveillance, and stewardship-driven use of systemic antifungal drugs, while Canada emphasizes stewardship, safety, and equitable access across provincial healthcare systems. Mexico and Brazil show growing demand through expanding private healthcare, public infectious disease programs, diabetes management needs, and ongoing attention to HIV-associated and hospital-acquired fungal infections. The United Kingdom, Germany, France, Italy, and Spain support evidence-based prescribing through strong specialist networks, clinical microbiology capacity, and guideline-led hospital practice, while Russia remains influenced by hospital procurement, domestic supply dynamics, and regional access variation.

China and India are pivotal because of scale, generic manufacturing, expanding tertiary care, rising oncology services, and growing awareness of invasive fungal disease. Japan prioritizes quality, safety, pharmacovigilance, and aging-population needs, Australia maintains strong stewardship and surveillance systems with high diagnostic standards, and South Korea combines advanced diagnostics with high hospital technology adoption and specialist infectious disease care. Across these countries, antifungal drug uptake depends on resistance patterns, reimbursement, prescriber education, availability of rapid diagnostics, susceptibility testing, and reliable supply of both innovative and essential antifungal therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms of action, oral step-down options, improved safety profiles, broad activity against resistant pathogens, and formulations that reduce hospitalization or simplify outpatient care. Investment in rapid diagnostics, susceptibility testing, therapeutic drug monitoring, and real-world evidence can strengthen clinical positioning and support stewardship-aligned adoption.

Commercial teams should segment opportunities by invasive fungal disease, recurrent mucosal infection, dermatology, and high-risk hospital populations such as transplant, oncology, ICU, and advanced HIV patients. Partnerships with diagnostic developers, transplant centers, oncology networks, clinical mycology laboratories, and public health agencies can improve pathway integration. Manufacturers should also protect supply continuity for essential antifungals, as shortages can directly affect outcomes in life-threatening fungal infections.

Research Methodology

This executive summary is built on secondary research from regulatory announcements, public health agencies, peer-reviewed infectious disease literature, clinical guideline trends, and pharmaceutical pipeline intelligence. Priority sources include WHO pathogen prioritization, CDC antimicrobial resistance communications, FDA drug approval information, regional public health surveillance, and published evidence on invasive fungal disease burden, treatment limitations, and antifungal resistance.

Market interpretation combines disease epidemiology, treatment class analysis, regional healthcare capacity, reimbursement conditions, diagnostic availability, stewardship practices, and innovation signals. Findings are synthesized to identify demand drivers, adoption barriers, regional priorities, and strategic opportunities while avoiding unsupported market-size claims, unverified growth estimates, and company-specific positioning.

Conclusion

Antifungal drugs are becoming a higher-priority pharmaceutical category as resistance, immunosuppression, hospital-acquired fungal infections, and diagnostic modernization converge. The market is no longer defined only by legacy azoles and polyenes; it is increasingly shaped by targeted therapies, rapid diagnostics, AI-enabled discovery, improved dosing strategies, and stewardship-led prescribing.

Organizations that combine clinical differentiation with access, surveillance, and evidence generation will be best positioned. The strongest opportunities will come from therapies that address resistant pathogens, reduce toxicity, simplify dosing, support oral or outpatient management, and fit real-world care pathways across hospitals, outpatient clinics, and resource-constrained settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antifungal Drugs Market, by Drug Class
7.1. Allylamines
7.2. Azoles
7.3. Echinocandins
7.4. Polyenes
8. Antifungal Drugs Market, by Dosage Form
8.1. Capsule
8.2. Cream
8.3. Ointment
8.4. Powder
8.5. Suspension
8.6. Tablet
9. Antifungal Drugs Market, by Species
9.1. Candida spp.
9.2. Aspergillus spp.
9.3. Cryptococcus spp.
9.4. Dermatophytes
9.5. Mucorales
10. Antifungal Drugs Market, by Route of Administration
10.1. Oral
10.2. Parenteral
10.3. Intravaginal
11. Antifungal Drugs Market, by Therapeutic Area
11.1. Aspergillosis
11.2. Candidiasis
11.2.1. Oropharyngeal
11.2.2. Systemic
11.2.3. Vulvovaginal
11.3. Cryptococcosis
11.4. Dermatophytosis
11.4.1. Tinea Corporis
11.4.2. Tinea Pedis
12. Antifungal Drugs Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Antifungal Drugs Market, by End Use
13.1. Hospitals
13.2. Specialty Clinics
13.3. Homecare
14. Antifungal Drugs Market, by Patient Age Group
14.1. Adult
14.2. Pediatric
14.3. Geriatric
15. Asia-Pacific Antifungal Drugs Market
16. North America Antifungal Drugs Market
17. Latin America Antifungal Drugs Market
18. Europe Antifungal Drugs Market
19. Middle East Antifungal Drugs Market
20. Africa Antifungal Drugs Market
21. ASEAN Antifungal Drugs Market
22. GCC Antifungal Drugs Market
23. European Union Antifungal Drugs Market
24. BRICS Antifungal Drugs Market
25. G7 Antifungal Drugs Market
26. NATO Antifungal Drugs Market
27. United States Antifungal Drugs Market
28. Canada Antifungal Drugs Market
29. Mexico Antifungal Drugs Market
30. Brazil Antifungal Drugs Market
31. United Kingdom Antifungal Drugs Market
32. Germany Antifungal Drugs Market
33. France Antifungal Drugs Market
34. Russia Antifungal Drugs Market
35. Italy Antifungal Drugs Market
36. Spain Antifungal Drugs Market
37. China Antifungal Drugs Market
38. India Antifungal Drugs Market
39. Japan Antifungal Drugs Market
40. Australia Antifungal Drugs Market
41. South Korea Antifungal Drugs Market
42. Competitive Landscape
42.1. Market Concentration Analysis, 2025
42.1.1. Concentration Ratio (CR)
42.1.2. Herfindahl Hirschman Index (HHI)
42.2. Recent Developments & Impact Analysis, 2025
42.3. Product Portfolio Analysis, 2025
42.4. Benchmarking Analysis, 2025
43. Company Profiles
43.1. Astellas Pharma Inc.
43.2. Aurobindo Pharma
43.3. Basilea Pharmaceutica Ltd.
43.4. Bayer AG
43.5. Cipla Limited
43.6. Dr. Reddy's Laboratories Ltd.
43.7. F. Hoffmann-La Roche AG
43.8. FUJIFILM Wako Pure Chemical Corporation
43.9. Gilead Sciences, Inc.
43.10. GlaxoSmithKline plc
43.11. Glenmark Pharmaceuticals Limited
43.12. Hikma Pharmaceuticals PLC
43.13. Johnson & Johnson Services Inc.
43.14. KAKEN PHARMACEUTICAL CO., LTD.
43.15. Lupin Ltd.
43.16. Mayne Pharma Group Limited
43.17. Melinta Therapeutics
43.18. Merck & Co., Inc.
43.19. Mycovia Pharmaceuticals, Inc.
43.20. Novartis AG
43.21. Pfizer Inc.
43.22. Sandoz Group AG
43.23. Sanofi S.A.
43.24. SCYNEXIS, Inc.
43.25. Sun Pharmaceutical Industries Ltd.
43.26. Teva Pharmaceutical Industries Ltd.
43.27. Viatris Inc.
43.28. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIFUNGAL DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIFUNGAL DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIFUNGAL DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2025 VS 2032 (%)
FIGURE 27. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 29. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. ITALY ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. CHINA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. INDIA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ALLYLAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ALLYLAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ALLYLAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ECHINOCANDINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ECHINOCANDINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ECHINOCANDINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL POLYENES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANDIDA SPP. MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANDIDA SPP. MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANDIDA SPP. MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ASPERGILLUS SPP. MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ASPERGILLUS SPP. MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ASPERGILLUS SPP. MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CRYPTOCOCCUS SPP. MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CRYPTOCOCCUS SPP. MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CRYPTOCOCCUS SPP. MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DERMATOPHYTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DERMATOPHYTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DERMATOPHYTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MUCORALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MUCORALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MUCORALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INTRAVAGINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INTRAVAGINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INTRAVAGINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ASPERGILLOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ASPERGILLOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ASPERGILLOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANDIDIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANDIDIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANDIDIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL OROPHARYNGEAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL OROPHARYNGEAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL OROPHARYNGEAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SYSTEMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SYSTEMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SYSTEMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL VULVOVAGINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL VULVOVAGINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL VULVOVAGINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DERMATOPHYTOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DERMATOPHYTOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL DERMATOPHYTOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL TINEA CORPORIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL TINEA CORPORIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL TINEA CORPORIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL TINEA PEDIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL TINEA PEDIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL TINEA PEDIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 154. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 157. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 158. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 160. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 161. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 164. EUROPE ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 176. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 177. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 178. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 179. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 180. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 182. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 183. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 186. AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 187. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 188. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 190. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 191. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 193. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 197. ASEAN ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 198. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 199. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 201. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 202. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 204. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 205. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 206. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 208. GCC ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 220. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 221. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 222. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 223. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 224. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 226. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 227. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 228. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 230. BRICS ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 231. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 232. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 233. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 234. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 235. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 237. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 238. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 239. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 241. G7 ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 242. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 243. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 244. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 245. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 246. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 248. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 249. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 250. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 252. NATO ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 264. CANADA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 265. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 267. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 268. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 269. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 270. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 271. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 272. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 273. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 274. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 275. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 276. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 277. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 278. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 279. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 280. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 281. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 282. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 283. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 284. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 285. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 286. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 287. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 288. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 289. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 290. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 291. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 292. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 293. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 294. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 295. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 296. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 308. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 309. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 310. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 311. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 312. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 313. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 314. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 315. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 316. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 317. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 318. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 319. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 320. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 321. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 322. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 323. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 324. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 325. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 326. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 327. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 328. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 329. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 330. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 331. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 332. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 333. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 334. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 335. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 336. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 337. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 338. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 339. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 340. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 341. ITALY ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 342. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 343. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 344. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 345. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 346. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 347. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 348. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 349. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 350. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 351. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 352. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 353. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 354. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 355. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 356. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 357. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 358. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 359. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 360. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 361. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 362. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 363. CHINA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 364. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 365. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 366. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 367. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 368. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 369. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, 2018-2032 (USD MILLION)
TABLE 370. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, 2018-2032 (USD MILLION)
TABLE 371. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 372. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
TABLE 373. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 374. INDIA ANTIFUNGAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 375. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 376. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 377. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 378. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 379. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY T

Companies Mentioned

The companies featured in this Antifungal Drugs market report include:
  • Astellas Pharma Inc.
  • Aurobindo Pharma
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • FUJIFILM Wako Pure Chemical Corporation
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services Inc.
  • KAKEN PHARMACEUTICAL CO., LTD.
  • Lupin Ltd.
  • Mayne Pharma Group Limited
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sandoz Group AG
  • Sanofi S.A.
  • SCYNEXIS, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages189
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 17.81 Billion
Forecasted Market Value ( USD ) by 2032 $ 25.93 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Antifungal Drugs Market Report by Drug Class, Indication, and Region 2026-2034 - Product Image

Antifungal Drugs Market Report by Drug Class, Indication, and Region 2026-2034

  • Report
  • 140 Pages
  • Global
From
Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class, Indication, Dosage Form, Distribution Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class, Indication, Dosage Form, Distribution Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
AntiFungal Drugs Market Outlook, 2030 - Product Image

AntiFungal Drugs Market Outlook, 2030

  • Report
  • 193 Pages
  • Global
From
Antifungal Drugs for Skin Market - Global Forecast 2025-2030 - Product Image

Antifungal Drugs for Skin Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Antifungal Drugs - Global Strategic Business Report - Product Image

Antifungal Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From

About the Antifungal Drug Market

The Antifungal Drug market is a subset of the larger Infectious Diseases Drugs market. Antifungal drugs are used to treat fungal infections, which can range from mild to life-threatening. These drugs work by either killing the fungus or preventing its growth. Common antifungal drugs include azoles, polyenes, and echinocandins. Azoles are the most commonly prescribed antifungal drugs, and are used to treat a wide range of fungal infections. Polyenes are used to treat more serious fungal infections, while echinocandins are used to treat severe fungal infections. The Antifungal Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, GlaxoSmithKline, and AstraZeneca. Other companies in the market include Bayer, Sanofi, Allergan, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.